Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HDAC inhibitor
Romidepsin strongly inhibits HDAC1 and HDAC2 with IC5N/A of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC5N/A 25 nM and 79N/A nM, respectively.- Dan Lu, .et al. , Sci Adv, 2024, Oct 25;10(43):eadp2229 PMID: 39454005
- Yu-Fang Liu, .et al. , J Biochem Mol Toxicol, 2022, Jun;36(6):e23044 PMID: 35499365
- David Diaz-Carballo, .et al. , Commun Biol, 2021, Mar 3;4(1):276 PMID: 33658617
- Eva Hesping, .et al. , Int J Parasitol Drugs Drug Resist, 2020, 14: 249-256
- Shariful Islam, .et al. , Blood Adv, 2020, 4(20): 5297-5310 PMID: 33108458
- Elena Netchiporouk, .et al. , Oncotarget, 2017, Nov 10; 8(56): 95981-95998 PMID: 29221181
- Ivan V. Litvinov, .et al. , Clin Cancer Res, 2014, 20(14): 3799-3808 PMID: 24850846
- Ivan V Litvinov, .et al. , Cell Cycle., 2014, 15; 13(18): 2975-2982 PMID: 25486484
-
peptide Oxytocin Receptor Inhibitor
Atosiban is a peptide Oxytocin Receptor Inhibitor.- G Perez-Hernandez, .et al. , J Dairy Sci, 2023, Dec;106(12):9855-9867 PMID: 37641323
-
Dynamin inhibitor
Dynamin Inhibitory Peptide is a peptide inhibitor of the GTPase dynamin. -
PKA inhibitor
PKA inhibitor fragment (6-22) amide is a synthetic peptide that acts as a protein kinase inhibitor. -
PKC inhibitor
PKC (19-36), pseudosubstrate peptide inhibitor of protein kinase C (IC50 = 0.18 uM). -
Ca 2+ /Mg 2+ -ATPase inhibitor
Glucagon (19-29) (human) is a potent Ca 2+ /Mg 2+ -ATPase inhibitor. -
14-3-3 protein Inhibitor
Difopein, dimeric version of R18 peptide that binds to 14.3.3 proteins with high affinity.- William J Stone, .et al. , J Neurochem, 2025, Sep;169(9):e70228 PMID: 40931680
-
Non-peptide calpain inhibitor
PD 150606 is a cell-permeable, non-competitive, selective, non-peptide Ca2+ dependent calpain inhibitor for calpain-1 and for calpain-2 directed towards the Ca2+ binding sites of calpain.- Hisamatsu Y, .et al. , Bioconjug Chem, 2017, Feb 15;28(2):507-523 PMID: 28032992
-
Bax inhibitor
Bax inhibitor peptide P5, cell-permeable synthetic peptide inhibitor of Bax translocation to mitochondria; designed from Ku70, a protein that is suggested to suppress the mitochondrial translocation of Bax. Inhibits Bax-mediated apoptosis in vitro. -
Bax inhibitor
Bax inhibitor peptide V5, cell-permeable synthetic peptide inhibitor of Bax translocation to mitochondria; designed from Ku70, a protein that is suggested to suppress the mitochondrial translocation of Bax. Inhibits Bax-mediated apoptosis in vitro. -
Bax inhibitor
Bax inhibitor peptide, negative control, negative control peptide for the Bax inhibitor peptides V5 and P5 , which inhibit Bax translocation to mitochondria and Bax-mediated apoptosis in vitro. -
Inhibits integrin binding to RGD motifs
RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.- Kan Zhang, .et al. , Exp Neurol, 2021, Feb 26;340:113659 PMID: 33640375
-
JNK inhibitor
c-JUN peptide is a peptide comprising residues 33 - 57 of the JNK binding (δ) domain of human c-Jun. -
α1β1 inhibitor
Highly potent integrin α1β1 inhibitor (IC50 = 0.8 nM for α1β1 binding to type IV collagen). Selective for α1β1 over α2β1, αIIbβ3, αvβ3, α4β1, α5β6, α9β1 and α4β7. Inhibits FGF2-stimulated angiogenesis in the chicken chorioallantoic model. Displays antitumor efficacy in a synergistic mouse model of Lewis lung carcinoma; blocks human melanoma growth in nude mice.- Stephanie W Watts, .et al. , Pharmacol Res, 2024, Jun 14:206:107269 PMID: 38880313
-
Fibronectin Inhibitor
RGDS peptide inhibits thrombin-induced binding of platelets to fibronectin, fibrinogen α, and von Willebrand factor with IC50 value of 10 μM. -
peptide deformylase inhibitor
Lanopepden (GSK 1322322) is a peptide deformylase inhibitor active against Staphylococcus aureus strains with MICs of 1 and 1 mg/L for ATCC 29213 and ATCC 25923 strain, respectively. -
integrin-ligand interactions inhibitor
RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and plays an important role in cell adhesion, migration, growth, and differentiation. -
NF-κB2 inhibitor
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research. -
PAI-1 inhibitor
Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling. -
Primates' C3 Inhibitor
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates' complement system. Compstatin exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively.
-
MUC1-C oncoprotein inhibitor
GO-203 TFA is a potent MUC1-C oncoprotein inhibitor. GO-203 TFA is an anti-cancer peptide for targeting intracellular proteins. -
Complement factor C3 inhibitor
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research -
FGFR3 inhibitor
VSPPLTLGQLLS is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation. -
CKLF1/CCL17 inhibitor
CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4. -
ACE inhibitor
Bradykinin potentiator B (Bradykinin potentiating peptide B) is venom of Agkistrodon halys blomhoffi. Bradykinin potentiator B is a potent ACE inhibitor. Bradykinin potentiator inhibits the activity of bradykinin inhibitory peptidase. -
anti-HIV-1 fusion inhibitor
Enfuvirtide (T20; DP178) acetate is an anti-HIV-1 fusion inhibitor peptide. -
HIV replication inhibitor
Feglymycin is a HIV replication inhibitor. Feglymycin is also an antibiotic peptide that has antibacterial activity (MIC: 32-64 μg/mL for Staphylococcus aureus). -
AnxA2 inhibitor
LCKLSL is an N-terminal hexapeptide that functions as a competitive inhibitor of annexin A2 (AnxA2). It effectively blocks the interaction between tissue plasminogen activator (tPA) and AnxA2, thereby inhibiting plasmin generation. Through suppression of the tPA–AnxA2–plasmin pathway, LCKLSL exhibits significant anti-angiogenic activity and may serve as a valuable tool for studying AnxA2-mediated fibrinolytic and vascular processes. -
C1q/MBL inhibitor
PIC1 PA is a 15-amino-acid peptide and a potent analog of PIC1 that inhibits classical pathway–mediated complement activation. It functions by disrupting the interaction between C1s-C1r-C1r-C1s/MASPs and the collagen-like region (CLR) of C1q or MBL. PIC1 PA specifically binds to the CLR of C1q, with a mean equilibrium dissociation constant (K\_D) of 33.3 nM for purified C1q. -
KRAS/ERK/RAS Inhibitor
LUNA18 is an orally bioavailable cyclic peptide that functions as a dual inhibitor of KRAS and ERK signaling pathways. It disrupts the interaction between RAS and guanine nucleotide exchange factors (GEFs), effectively inhibiting RAS activation and downstream signaling. In RAS-mutated cancer cells, LUNA18 reduces cell proliferation while modulating key signaling nodes, including phosphorylation of ERK and AKT. In preclinical studies, LUNA18 demonstrates potent anticancer activity, particularly in xenograft models, by blocking RAS-driven tumor growth. It shows significant cellular efficacy against cancer cell lines harboring KRAS mutations, including colon, gastric, pancreatic, and non-small cell lung cancers, highlighting its therapeutic potential as a targeted agent for RAS-driven malignancies. -
Bone resorption inhibitor
Chicken calcitonin is a peptide hormone involved in the regulation of calcium metabolism. It inhibits bone resorption by suppressing the motility and activity of osteoclasts, as demonstrated in neonatal rat models. This hormone plays a key role in maintaining bone homeostasis and is of interest in bone-related research. -
SETD8 Inhibitor
[Nle20] H4 peptide (16−23) is a potent inhibitor of the histone methyltransferase SETD8, exhibiting a Kd of 0.14 μM. This peptide competes with histone H4 for binding to the substrate site of SETD8, effectively blocking its methylation activity. As a result, [Nle20] H4 peptide (16−23) serves as a valuable tool in cancer research, offering potential applications in the development of therapeutic strategies targeting epigenetic modulation. -
Gastric Inhibitory Polypeptide
[Tyr0] Gastric Inhibitory Peptide (23-42), human is a variant of the glucose-dependent insulinotropic polypeptide (GIP) that primarily targets the regulation of gastric acid secretion. It acts as a weak inhibitor of gastric acid release while promoting insulin secretion in a glucose-dependent manner. This peptide is useful in research focused on diabetes and obesity, helping to elucidate the mechanisms of metabolic regulation and potential therapeutic interventions. -
IRF5 Inhibitory Peptide
PTD-N5-1 is an inhibitory peptide targeting Interferon Regulatory Factor 5 (IRF5). This compound effectively blocks β-glucan-induced IL-12 production in both interferon-gamma-primed wild-type and Clec2d-deficient bone marrow-derived dendritic cells (BMDCs). By suppressing IRF5-mediated IL-12 production, PTD-N5-1 plays a critical role in regulating antifungal immunity, making it valuable for research applications focused on immune response modulation. -
Inhibitor Peptide
PD-L1 inhibitory peptide is an inhibitor peptide that targets programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it effectively alleviates immunosuppression and enhances the antitumor activity of T cells. This peptide is valuable for cancer research, particularly in the study of immune checkpoint regulation and therapeutic interventions. -
IL-6 Inhibitor
Palmitoyl Tetrapeptide-3 is a synthetic peptide that acts as an interleukin-6 (IL-6) inhibitor, primarily targeting inflammatory pathways in skin cells. It effectively reduces IL-6 secretion in keratinocytes and mitigates the inflammatory response induced by UVB radiation exposure. This compound exhibits anti-inflammatory and anti-aging properties, promoting the production of elastic fibers in the papillary dermis, thereby contributing to a reduction in skin wrinkles and overall skin rejuvenation. Its applications include studies in dermatology, skin biology, and anti-aging research. -
IL-23R Inhibitor
IL-23R inhibitor peptide-1 is a potent interleukin-23 receptor inhibitor with an IC50 of 0.0069 μM. It is designed to modulate the signaling pathway of IL-23, which plays a critical role in the pathogenesis of various autoimmune diseases. This reagent is suitable for research applications focused on inflammatory responses and therapeutic strategies targeting IL-23 signaling. -
CD44-Hyaluronan Inhibitor
IGFBP-3 peptide is an 18-amino acid fragment of insulin-like growth factor binding protein-3, known to inhibit the interaction between CD44 and hyaluronan. This peptide effectively binds to Humanin and hyaluronan, thereby blocking their functional interactions. IGFBP-3 peptide serves as a useful tool for researching CD44-related signaling pathways and its role in cellular adhesion and migration. -
Lyn Kinase Inhibitor
Lyn Peptide Inhibitor is a selective inhibitor of Lyn kinase that specifically targets the Lyn-coupled IL-5 receptor signaling pathway. This compound effectively blocks Lyn activation and disrupts the interaction between Lyn tyrosine kinase and the βc subunit of IL-3/GM-CSF/IL-5 receptors. The Lyn Peptide Inhibitor is valuable for investigating mechanisms underlying asthma, allergic reactions, and various eosinophilic disorders, providing insights into potential therapeutic approaches. -
Phosphopeptide Inhibitor
Caffeic acid-pYEEIE is a phosphopeptide inhibitor that demonstrates strong binding affinity for the GST-Lck-SH2 domain. This compound serves as a valuable tool in research focused on T cell signaling and immune response modulation. Its ability to selectively inhibit specific protein interactions makes it instrumental in studying the mechanisms underlying various cellular processes and disorders. -
Peptide Inhibitor
MEK1 Derived Peptide Inhibitor 1 is a selective peptide inhibitor targeting MEK1, effectively blocking the in vitro activation of ERK2 with an IC50 value of 30 μM. This compound is valuable for studies focused on the MEK/ERK signaling pathway, allowing researchers to investigate cellular processes regulated by this pathway. Its cell-permeable properties make it suitable for various biological applications in cancer research and signal transduction studies. -
Myostatin Inhibitor
Myostatin Inhibitory Peptide 2 is a specific inhibitor of myostatin, exhibiting a dissociation constant (Kd) of 35.9 nM. This peptide plays a significant role in regulating muscle growth and is particularly beneficial for research focused on muscle atrophic disorders. By modulating myostatin activity, it provides insights into potential therapeutic approaches for enhancing muscle regeneration and combatting muscle-wasting conditions. -
TGF-β1 Inhibitory Peptide
P17 Peptide is a selective inhibitor of human TGF-β1, functioning by blocking its activity. This peptide is valuable for studying the role of TGF-β1 in various biological processes and disease states, including fibrosis and cancer. Its inhibitory effects facilitate research into therapeutic strategies targeting TGF-β signaling pathways. -
IL-23 Inhibitor
IL-23 cyclic peptide inhibitor 105 targets the interleukin-23 (IL-23) pathway, serving as a specific inhibitor of this pro-inflammatory cytokine. It exhibits significant potential in modulating inflammatory responses associated with disorders such as inflammatory bowel disease (IBD). This compound is a valuable tool for researchers investigating the role of IL-23 in various inflammatory conditions and developing therapeutic strategies targeting IL-23 signaling.
